Literature DB >> 20827362

Update on Dual Delayed-Release PPI Formulations.

Colin W Howden1.   

Abstract

Year:  2010        PMID： 20827362      PMCID： PMC2933755     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  8 in total

Review 1.  Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.

Authors:  Cheryl Abel; Alicia R Desilets; Kristine Willett
Journal:  Ann Pharmacother       Date:  2010-04-06       Impact factor: 3.154

Review 2.  Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.

Authors:  D C Metz; M Vakily; T Dixit; D Mulford
Journal:  Aliment Pharmacol Ther       Date:  2009-02-26       Impact factor: 8.171

3.  Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

Authors:  P Sharma; N J Shaheen; M C Perez; B L Pilmer; M Lee; S N Atkinson; D Peura
Journal:  Aliment Pharmacol Ther       Date:  2009-04-01       Impact factor: 8.171

4.  Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.

Authors:  D C Metz; C W Howden; M C Perez; L Larsen; J O'Neil; S N Atkinson
Journal:  Aliment Pharmacol Ther       Date:  2009-02-07       Impact factor: 8.171

5.  Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.

Authors:  R Fass; W D Chey; S F Zakko; N Andhivarothai; R N Palmer; M C Perez; S N Atkinson
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

6.  Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.

Authors:  D A Peura; D C Metz; A H Dabholkar; M M Paris; P Yu; S N Atkinson
Journal:  Aliment Pharmacol Ther       Date:  2009-09-04       Impact factor: 8.171

7.  Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.

Authors:  C W Howden; L M Larsen; M C Perez; R Palmer; S N Atkinson
Journal:  Aliment Pharmacol Ther       Date:  2009-08-14       Impact factor: 8.171

8.  Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.

Authors:  R D Lee; M Vakily; D Mulford; J Wu; S N Atkinson
Journal:  Aliment Pharmacol Ther       Date:  2008-01-20       Impact factor: 8.171
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.